Incyte Corporation

58.10-0.7100-1.21%Vol 2.29M1Y Perf -12.76%
Sep 22nd, 2023 16:00 DELAYED
BID57.36 ASK58.89
Open58.77 Previous Close58.81
Pre-Market- After-Market58.09
 - -  -0.01 -0.02%
Target Price
82.45 
Analyst Rating
Moderate Buy 2.07
Potential %
41.91 
Finscreener Ranking
★★★+     51.51
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     56.36
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     70.21
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
-1.59 
Earnings Rating
Strong Buy
Market Cap13.02B 
Earnings Date
7th Nov 2023
Alpha-0.00 Standard Deviation0.09
Beta0.69 

Today's Price Range

57.9159.34

52W Range

58.5486.29

5 Year PE Ratio Range

-44.50283.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.11%
1 Month
-10.13%
3 Months
-6.97%
6 Months
-19.60%
1 Year
-12.76%
3 Years
-32.42%
5 Years
-12.75%
10 Years
63.94%

TickerPriceChg.Chg.%
INCY58.10-0.7100-1.21
AAPL174.790.86000.49
GOOG131.25-0.1100-0.08
MSFT317.01-2.5200-0.79
XOM114.940.18000.16
WFC41.23-1.0900-2.58
JNJ160.50-1.1600-0.72
FB196.640.99000.51
GE111.25-1.7400-1.54
JPM145.73-1.4100-0.96
Financial StrengthValueIndustryS&P 500US Markets
3.60
3.80
0.01
0.01
207.70
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
94.20
17.20
19.10
2.70
12.65
RevenueValueIndustryS&P 500US Markets
2.47B
11.09
14.26
18.47
Earnings HistoryEstimateReportedSurprise %
Q02 20230.690.7711.59
Q01 20230.680.18-73.53
Q04 20220.430.442.33
Q03 20220.540.44-18.52
Q02 20220.610.8539.34
Q01 20220.340.4017.65
Q04 20210.65-0.07-110.77
Q03 20210.551.0081.82
Earnings Per EndEstimateRevision %Trend
9/2023 QR0.911.11Positive
12/2023 QR1.090.93Positive
12/2023 FY2.985.30Positive
12/2024 FY3.97-1.98Negative
Next Report Date7th Nov 2023
Estimated EPS Next Report0.91
Estimates Count7
EPS Growth Next 5 Years %7.00
Volume Overview
Volume2.29M
Shares Outstanding224.09K
Shares Float184.87M
Trades Count31.20K
Dollar Volume133.17M
Avg. Volume1.93M
Avg. Weekly Volume2.50M
Avg. Monthly Volume1.71M
Avg. Quarterly Volume1.57M

Incyte Corporation (NASDAQ: INCY) stock closed at 58.1 per share at the end of the most recent trading day (a -1.21% change compared to the prior day closing price) with a volume of 2.29M shares and market capitalization of 13.02B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1773 people. Incyte Corporation CEO is Herve Hoppenot.

The one-year performance of Incyte Corporation stock is -12.76%, while year-to-date (YTD) performance is -27.66%. INCY stock has a five-year performance of -12.75%. Its 52-week range is between 58.54 and 86.29, which gives INCY stock a 52-week price range ratio of -1.59%

Incyte Corporation currently has a PE ratio of 20.60, a price-to-book (PB) ratio of 4.26, a price-to-sale (PS) ratio of 7.11, a price to cashflow ratio of 22.50, a PEG ratio of 2.94, a ROA of 19.32%, a ROC of 23.53% and a ROE of 25.41%. The company’s profit margin is 12.65%, its EBITDA margin is 19.10%, and its revenue ttm is $2.47 Billion , which makes it $11.09 revenue per share.

Of the last four earnings reports from Incyte Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.91 for the next earnings report. Incyte Corporation’s next earnings report date is 07th Nov 2023.

The consensus rating of Wall Street analysts for Incyte Corporation is Moderate Buy (2.07), with a target price of $82.45, which is +41.91% compared to the current price. The earnings rating for Incyte Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Incyte Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Incyte Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 12.13, ATR14 : 1.34, CCI20 : -179.28, Chaikin Money Flow : -0.14, MACD : -1.28, Money Flow Index : 32.83, ROC : -8.06, RSI : 28.05, STOCH (14,3) : 2.62, STOCH RSI : 0.00, UO : 28.96, Williams %R : -97.38), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Incyte Corporation in the last 12-months were: Dashyant Dhanak (Option Excercise at a value of $241 596), Dashyant Dhanak (Sold 2 419 shares of value $205 615 ), Dhanak Dashyant (Option Excercise at a value of $241 596), Dhanak Dashyant (Sold 2 419 shares of value $205 615 ), Maria E. Pasquale (Option Excercise at a value of $4 405 224), Maria E. Pasquale (Sold 60 024 shares of value $5 086 567 ), Pasquale Maria (Option Excercise at a value of $4 465 197), Pasquale Maria (Sold 60 826 shares of value $5 153 983 ), Stein Steven (Sold 49 910 shares of value $3 626 888 ), Steven H. Stein (Sold 28 399 shares of value $2 265 672 ), Swain Paula (Sold 8 449 shares of value $550 283 ), Thomas Tray (Sold 1 223 shares of value $100 482 ), Vijay Iyengar (Option Excercise at a value of $480 340), Vijay Iyengar (Sold 7 000 shares of value $595 000 ), Vijay K. Iyengar (Option Excercise at a value of $1 533 797), Vijay K. Iyengar (Sold 24 324 shares of value $1 994 739 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (46.67 %)
7 (46.67 %)
6 (37.50 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
8 (53.33 %)
8 (53.33 %)
10 (62.50 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.07
Moderate Buy
2.07
Moderate Buy
2.25

Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.

CEO: Herve Hoppenot

Telephone: +1 302 498-6700

Address: 1801 Augustine Cut-Off, Wilmington 19803, DE, US

Number of employees: 1 773

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

54%46%

Bearish Bullish

59%41%

 

TipRanks News for INCY

Wed, 02 Aug 2023 11:15 GMT Incyte (INCY) Gets a Hold from BMO Capital

- TipRanks. All rights reserved.

Tue, 25 Jul 2023 11:10 GMT Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Alnylam Pharma (ALNY)

- TipRanks. All rights reserved.

News

Stocktwits